Full Press Release Details
Pharma Announces Participation in May 2024 Investor Conferences
and New York, NY, May 8, 2024 - OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical
company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market,
and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an
FDA approved therapy, today announced upcoming presentations at two investor conferences in May 2024.
Aegis Capital Virtual Healthcare Conference
Wednesday May 8, 2024, 11 AM EST
Gary Jacob, PhD, Chief Executive Officer
Citizens JMP Securities Life Sciences Conference
Monday May 13, 2024, 10:30 AM EST
Gary Jacob, PhD, Chief Executive Officer
Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED
and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel
molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway
for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please
visit www.okyopharma.com.
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 | ||
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |